Facebook
Twitter
Telegram
Report an ErrorMatinas BioPharma Holdings Balance Sheet 2011-2024 | MTNB
Annual Balance Sheet Matinas BioPharma Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-4.11 M | -6.25 M | -20.5 M | -8.68 M | -17.9 M | -12.1 M | -7.04 M | -3.96 M | -3.22 M | -2.53 M | -10.8 M | - | - |
Long Term Debt |
18 K | 22 K | 3 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
656 K | 562 K | 539 K | 391 K | 424 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
3.24 M | 3.9 M | 4.48 M | 3.67 M | 4.09 M | 962 K | 1.52 M | 1.22 M | 1.21 M | 15.3 K | - | - | - |
Total Current Liabilities |
2.62 M | 4.29 M | 4.35 M | 3.57 M | 3.1 M | 2.84 M | 2.22 M | 1.44 M | 1.13 M | 1.12 M | - | - | - |
Total Liabilities |
5.86 M | 8.18 M | 8.83 M | 7.24 M | 7.19 M | 3.8 M | 3.74 M | 2.67 M | 2.33 M | 1.13 M | 859 K | - | - |
Deferred Revenue |
- | - | - | 643 K | 100 K | - | 29.9 K | - | - | - | - | - | - |
Retained Earnings |
-176 M | -153 M | -132 M | -108 M | -84.4 M | -65.9 M | -51.3 M | -35.2 M | -23.2 M | -14.1 M | -3.83 M | - | - |
Total Assets |
25.1 M | 44.8 M | 61.3 M | 71 M | 40.2 M | 19.9 M | 14.4 M | 9.82 M | 8.41 M | 3.36 M | 11.3 M | - | - |
Cash and Cash Equivalents |
4.79 M | 6.83 M | 21 M | 12.4 M | 22.2 M | 12.4 M | 7.31 M | 4.11 M | 3.23 M | 2.59 M | 10.8 M | - | - |
Book Value |
19.2 M | 36.6 M | 52.5 M | 63.7 M | 33.1 M | 16.1 M | 10.7 M | 7.15 M | 6.07 M | 2.23 M | 10.5 M | - | - |
Total Shareholders Equity |
19.2 M | 36.6 M | 52.5 M | 63.7 M | 33.1 M | 16.1 M | 10.7 M | 7.15 M | 6.07 M | 2.23 M | 10.5 M | -117 K | - |
All numbers in USD currency
Quarterly Balance Sheet Matinas BioPharma Holdings
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
19 K | 20 K | 21 K | 22 K | 3.68 M | 3.84 M | 3.99 M | 2.62 K | 5.74 K | 11.5 K | 17.1 K | 23.7 K | 23.7 K | 23.7 K | 23.7 K | 54.5 K | 54.5 K | 54.5 K | 54.5 K | 108 K | 108 K | 108 K | 108 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
3.41 M | 3.58 M | 3.74 M | 3.9 M | 4.03 M | 4.18 M | 4.33 M | 4.48 M | 4.63 M | 3.48 M | 3.57 M | 3.67 M | 3.67 M | 3.67 M | 3.67 M | 4.09 M | 4.09 M | 4.09 M | 4.09 M | 962 K | 962 K | 962 K | 962 K | 1.97 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
6.64 M | 6.17 M | 5.64 M | 8.18 M | 8.93 M | 9.57 M | 8.1 M | 8.83 M | 8.73 M | 7.07 M | 5.79 M | 7.24 M | 7.24 M | 7.24 M | 7.24 M | 7.19 M | 7.19 M | 7.19 M | 7.19 M | 3.8 M | 3.8 M | 3.8 M | 3.8 M | 3.74 M | 3.74 M | 3.74 M | 3.74 M | 2.67 M | 2.67 M | 2.67 M | 2.67 M | 2.33 M | 2.33 M | 2.33 M | 2.33 M | 1.13 M | 1.13 M | 1.13 M | 1.13 M | 859 K | 859 K | 859 K | 859 K | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | 721 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.9 K | 29.9 K | 29.9 K | 29.9 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-170 M | -164 M | -158 M | -153 M | -149 M | -144 M | -138 M | -132 M | -125 M | -118 M | -112 M | -108 M | -108 M | -108 M | -108 M | -84.4 M | -84.4 M | -84.4 M | -84.4 M | -65.9 M | -65.9 M | -65.9 M | -65.9 M | -51.3 M | -51.3 M | -51.3 M | -51.3 M | -35.2 M | -35.2 M | 35.2 M | -35.2 M | -23.2 M | -23.2 M | -23.2 M | -23.2 M | -14.1 M | -14.1 M | -14.1 M | -14.1 M | -3.83 M | -3.83 M | -3.83 M | -3.83 M | - | - | - | - | - | - | - | - |
Total Assets |
29.8 M | 34 M | 38.3 M | 44.8 M | 47.5 M | 52.4 M | 55.8 M | 61.3 M | 67 M | 70 M | 72.4 M | 71 M | 71 M | 71 M | 71 M | 40.2 M | 40.2 M | 40.2 M | 40.2 M | 19.9 M | 19.9 M | 19.9 M | 19.9 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 9.82 M | 9.82 M | 9.82 M | 9.82 M | 8.41 M | 8.41 M | 8.41 M | 8.41 M | 3.36 M | 3.36 M | 3.36 M | 3.36 M | 11.3 M | 11.3 M | 11.3 M | 11.3 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
6.41 M | 9.74 M | 5.74 M | 6.83 M | 11.2 M | 10.4 M | 19.3 M | 21 M | 24.9 M | 30.4 M | 23.4 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 12.4 M | 12.4 M | 12.4 M | 12.4 M | 7.31 M | 7.31 M | 7.31 M | 7.31 M | 4.1 M | 4.11 M | 4.11 M | 4.11 M | 3.23 M | 3.23 M | 3.23 M | 3.23 M | 2.59 M | 2.59 M | 2.59 M | 2.59 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 424 K | - | - | - | - | - | - | - |
Book Value |
23.2 M | 27.9 M | 32.6 M | 36.6 M | 38.6 M | 42.8 M | 47.7 M | 52.5 M | 58.3 M | 62.9 M | 66.6 M | 63.7 M | 63.7 M | 63.7 M | 63.7 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 7.15 M | 7.15 M | 7.15 M | 7.15 M | 6.07 M | 6.07 M | 6.07 M | 6.07 M | 2.23 M | 2.23 M | 2.23 M | 2.23 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
23.2 M | 27.9 M | 32.6 M | 36.6 M | 38.6 M | 42.8 M | 47.7 M | 52.5 M | 58.3 M | 62.9 M | 66.6 M | 63.7 M | 63.7 M | 63.7 M | 63.7 M | 33.1 M | 33.1 M | 33.1 M | 33.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 10.7 M | 10.7 M | 10.7 M | 10.7 M | 7.15 M | 7.15 M | 7.15 M | 7.15 M | 6.07 M | 6.07 M | 6.07 M | 6.07 M | 2.23 M | 2.23 M | 2.23 M | 2.23 M | 10.5 M | 10.5 M | 10.5 M | 10.5 M | -117 K | - | - | - | - | - | - | - |
All numbers in USD currency